See more : ResMed Inc. (RMD.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Instil Bio, Inc. (TIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Instil Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Empire Resources Limited (ERL.AX) Income Statement Analysis – Financial Results
- ChemoCentryx, Inc. (CCXI) Income Statement Analysis – Financial Results
- Milan Station Holdings Limited (1150.HK) Income Statement Analysis – Financial Results
- Saraiva Livreiros S.A. – em Recuperação Judicial (SLED3.SA) Income Statement Analysis – Financial Results
- Tivic Health Systems, Inc. (TIVC) Income Statement Analysis – Financial Results
Instil Bio, Inc. (TIL)
About Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 138.00K | 0.00 |
| Cost of Revenue | 4.76M | 5.99M | 2.75M | 0.00 | 20.00K |
| Gross Profit | -4.76M | -5.99M | -2.75M | 138.00K | -20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 39.60M | 141.06M | 107.25M | 19.40M | 4.03M |
| General & Administrative | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Other Expenses | 72.01M | -564.00K | -1.20M | -4.66M | -5.00K |
| Operating Expenses | 85.79M | 203.29M | 155.56M | 33.78M | 6.59M |
| Cost & Expenses | 90.54M | 203.29M | 155.56M | 33.78M | 6.59M |
| Interest Income | 8.87M | 3.66M | 0.00 | 70.00K | 68.00K |
| Interest Expense | 5.21M | 1.88M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.76M | 5.99M | 2.75M | 256.00K | 20.00K |
| EBITDA | -146.12M | -217.38M | -154.00M | -33.39M | -6.50M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -24,660.14% | 0.00% |
| Operating Income | -159.17M | -226.46M | -155.56M | -33.64M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -24,379.71% | 0.00% |
| Total Other Income/Expenses | 3.08M | 1.21M | -1.20M | -3.94M | 63.00K |
| Income Before Tax | -156.09M | -225.25M | -156.76M | -37.59M | -6.52M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -27,236.96% | 0.00% |
| Income Tax Expense | 0.00 | -2.07M | 39.00K | 151.00K | -68.00K |
| Net Income | -156.09M | -223.18M | -156.79M | -37.74M | -6.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -27,346.38% | 0.00% |
| EPS | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| EPS Diluted | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| Weighted Avg Shares Out | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
| Weighted Avg Shares Out (Dil) | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
Presentation to highlight correlates of response to TIL product attributes and elements of Instil Bio's cell therapy data analytics and computational platform Presentation to highlight correlates of response to TIL product attributes and elements of Instil Bio's cell therapy data...
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
DALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will be participating...
Instil Bio to Present at Upcoming Investor Conferences in November
DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate...
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma
At a Recent Cancer Research Conference, Instil Bio Stole the Show
The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
67% overall response rate and 19% complete response rate in 21 patients
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the closing of its...
US IPO Weekly Recap: The IPO Market Heats Up In An 11 IPO Week
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings.
TIL Stock Price Increased 32.2% In Market Debut
The stock price of Instil Bio Inc (NASDAQ: TIL) increased by 32.2% in its market debut. These are the details.
Instil Bio Announces Pricing of Upsized Initial Public Offering
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the pricing of its...
Source: https://incomestatements.info
Category: Stock Reports